Rathee Sunny, Dayaramani Richa
Centre for Medical Devices, National Institute of Pharmaceutical Education and Research-Ahmedabad (NIPER-A), Opposite Air Force Station, Palaj, Gandhinagar, 382055, Gujarat, India.
AAPS PharmSciTech. 2025 Jul 8;26(6):187. doi: 10.1208/s12249-025-03187-4.
Microneedle-based medical devices have gained significant attention as innovative tools for addressing challenges in wound healing, particularly in diabetic wound management. These devices offer a minimally invasive, patient-compliant platform for drug delivery, tissue regeneration, and real-time monitoring. This review provides a comprehensive overview of their design and applications, focusing on their role in modulating biological pathways and enzymatic markers essential for wound repair. Key biological pathways such as VEGF (Vascular Endothelial Growth Factor)-mediated angiogenesis, matrix metalloproteinase (MMP)-driven tissue remodeling, and inflammatory response regulation are discussed to elucidate the mechanisms underlying wound healing. The utility of biochemical markers, including oxidative stress indicators and growth factors, in evaluating wound progression is highlighted. Additionally, microneedles demonstrate unique advantages, such as enhanced bioavailability, precise drug delivery, and integration with biosensors for real-time feedback, making them ideal for chronic wound management. In the context of diabetic wounds, microneedle-based devices address specific challenges like impaired angiogenesis, prolonged inflammation, and delayed healing by facilitating localized delivery of therapeutic agents and monitoring critical biomarkers. Advanced material innovations and emerging technologies further enhance their performance and scalability. This review also examines the regulatory landscape and commercialization prospects of microneedle systems while outlining future directions, including novel materials and synergistic therapies. By bridging technological advancements with clinical needs, microneedle-based devices hold the potential to revolutionize wound care and improve outcomes in diabetic and other chronic wound conditions.
基于微针的医疗设备作为应对伤口愈合挑战,尤其是糖尿病伤口管理挑战的创新工具,已受到广泛关注。这些设备为药物递送、组织再生和实时监测提供了一个微创、患者依从性好的平台。本综述全面概述了它们的设计和应用,重点关注它们在调节伤口修复所必需的生物途径和酶标志物方面的作用。讨论了关键的生物途径,如血管内皮生长因子(VEGF)介导的血管生成、基质金属蛋白酶(MMP)驱动的组织重塑以及炎症反应调节,以阐明伤口愈合的潜在机制。强调了生化标志物,包括氧化应激指标和生长因子,在评估伤口进展中的作用。此外,微针具有独特的优势,如提高生物利用度、精确药物递送以及与生物传感器集成以实现实时反馈,使其成为慢性伤口管理的理想选择。在糖尿病伤口的背景下,基于微针的设备通过促进治疗剂的局部递送和监测关键生物标志物,解决了诸如血管生成受损、炎症延长和愈合延迟等特定挑战。先进的材料创新和新兴技术进一步提高了它们的性能和可扩展性。本综述还考察了微针系统的监管环境和商业化前景,同时概述了未来的方向,包括新型材料和协同疗法。通过将技术进步与临床需求相结合,基于微针的设备有可能彻底改变伤口护理,并改善糖尿病和其他慢性伤口状况的治疗效果。